Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Macrogenics (MGNX) Common Equity (2016 - 2025)

Macrogenics (MGNX) has disclosed Common Equity for 14 consecutive years, with $55.6 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 52.1% to $55.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $55.6 million through Dec 2025, down 52.1% year-over-year, with the annual reading at $55.6 million for FY2025, 52.1% down from the prior year.
  • Common Equity for Q4 2025 was $55.6 million at Macrogenics, down from $67.0 million in the prior quarter.
  • The five-year high for Common Equity was $350.5 million in Q1 2021, with the low at $46.6 million in Q2 2025.
  • Average Common Equity over 5 years is $153.1 million, with a median of $132.5 million recorded in 2022.
  • The sharpest move saw Common Equity surged 83.94% in 2021, then plummeted 66.29% in 2024.
  • Over 5 years, Common Equity stood at $239.6 million in 2021, then crashed by 40.73% to $142.0 million in 2022, then grew by 7.46% to $152.6 million in 2023, then decreased by 23.95% to $116.1 million in 2024, then plummeted by 52.1% to $55.6 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $55.6 million, $67.0 million, and $46.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.